학술논문
COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANON
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15244733